diagnost
test
pulmonari
tb
altern
endors
rapid
molecular
test
line
probe
assay
recommend
readili
avail
ii
tb
cultur
perform
follow
patient
neg
gene
xpert
mtbrif
nonresolv
pneumonia
ongo
suspicion
tb
iii
sputum
unavail
determin
tm
tblam
ag
aler
waltham
usa
test
perform
hivinfect
patient
count
stage
diseas
present
cap
pcp
typic
present
immunocompromis
patient
subacut
ill
constitut
symptom
dri
cough
characteris
bilater
infiltr
cxr
clinic
case
definit
use
clinic
diagnos
pcp
b
iii
diagnost
test
hivinfect
patient
fit
case
definit
pcp
suspect
clinic
ground
depend
local
avail
test
may
includ
immunofluoresc
assay
ifa
direct
fluoresc
antibodi
test
dfat
pcr
b
iii
prefer
specimen
diagnost
test
pcp
bronchoalveolar
lavag
fluid
bal
although
induc
expector
sputum
may
use
bronchoscopi
unavail
b
ii
limit
evid
support
use
betaglucan
diagnos
pcp
south
african
set
use
recommend
part
clinic
registri
trial
iii
initi
empir
therapi
cap
guid
set
patient
treat
age
use
antibiot
within
previou
day
presenc
comorbid
cardiovascular
diseas
chronic
respiratori
diseas
chronic
renal
failur
diabet
mellitu
hiv
infect
drug
intoler
empir
therapi
pcp
influenza
may
necessari
clinic
epidemiolog
criteria
met
rare
necessari
give
empir
treatment
tb
unless
miliari
pattern
cxr
initi
antibiot
therapi
patient
treat
home
year
old
without
antibiot
exposur
past
day
comorbid
receiv
oral
high
dose
amoxicillin
ii
patient
treat
home
year
old
without
antibiot
exposur
past
day
comorbid
set
low
macrolid
resist
could
receiv
oral
macrolideazalid
presenc
sever
betalactam
allergi
ii
patient
treat
home
year
old
receiv
antibiot
within
previou
day
comorbid
receiv
oral
amoxicillinclavulan
oral
second
gener
cephalosporin
ii
patient
whose
admiss
hospit
precipit
advanc
age
person
famili
prefer
inadequ
home
care
advers
social
circumst
nonsever
pneumonia
treat
oral
antibiot
describ
ii
patient
requir
admiss
hospit
year
old
without
antibiot
exposur
past
day
comorbid
receiv
intraven
ampicillin
penicillin
ivi
ampicillin
avail
ii
patient
requir
admiss
hospit
year
old
receiv
antibiot
within
previou
day
comorbid
receiv
intraven
amoxicillinclavulan
cefuroxim
thirdgener
cephalosporin
ceftriaxon
cefotaxim
ii
patient
sever
pneumonia
receiv
amoxicillinclavulan
cefuroxim
third
gener
cephalosporin
ceftriaxon
cefotaxim
plu
macrolid
antibiot
ii
respiratori
fluoroquinolon
moxifloxacin
levofloxacin
altern
therapi
activ
tuberculosi
agent
use
first
line
cap
may
use
patient
sever
betalactam
allergi
altern
betalactammacrolid
therapi
reserv
use
patient
altern
treatment
option
ii
antibiot
administ
earli
prefer
within
emerg
unit
patient
confirm
cap
ii
microbiolog
test
detect
caus
organ
may
possibl
chang
empir
definit
therapi
base
drug
suscept
test
caus
organ
identifi
microbiolog
test
antibiot
chang
narrowest
spectrum
agent
effect
treat
organ
ii
ceftarolin
recommend
direct
therapi
base
result
microbiolog
test
case
high
level
penicillin
resist
penicillin
mic
mgl
pneumonia
mrsa
ertapenem
recommend
direct
therapi
base
result
microbiolog
test
case
resist
enterobacteriacea
esblproduc
pathogen
add
therapi
pcp
tb
empir
therapi
pcp
ad
patient
fulfil
case
definit
withheld
base
neg
immunohistochem
stain
sputum
specimen
ii
empir
therapi
tb
prior
initi
test
rare
requir
unless
miliari
pattern
cxr
patient
sever
ill
tb
suspect
iii
add
empir
therapi
influenza
influenza
season
oseltamivir
provid
patient
sever
pneumonia
stop
pcr
test
nasopharyng
aspir
neg
ii
influenza
season
oseltamivir
provid
patient
moder
cap
suspect
influenza
specif
risk
factor
sever
diseas
stop
pcr
test
nasopharyng
aspir
neg
b
ii
given
signific
burden
diseas
caus
cap
mani
attempt
find
adjunct
therapi
improv
outcom
enough
evid
recommend
routin
use
statin
either
prevent
treatment
cap
ii
addit
macrolid
standard
betalactam
therapi
associ
better
outcom
patient
sever
cap
requir
icu
admiss
may
relat
antimicrobi
activ
macrolid
may
also
due
antiinflammatori
immunomodulatori
effect
ii
use
system
corticosteroid
eg
methylprednison
h
equival
consid
patient
sever
cap
requir
icu
admiss
unless
influenza
tuberculosi
like
histori
gastrointestin
bleed
within
previou
month
prompt
switch
intraven
oral
therapi
cornerston
antibiot
stewardship
use
minimum
effect
durat
therapi
patient
switch
intraven
oral
antibiot
haemodynam
stabl
respiratori
rate
temperatur
abl
take
oral
medic
patient
manag
commun
patient
admit
hospit
low
moder
sever
uncompl
pneumonia
day
appropri
antibiot
recommend
ii
treatment
durat
may
extend
beyond
day
specif
clinic
scenario
staphylococcu
aureu
bacteraemia
ii
patient
confirm
legionella
pneumonia
treat
azithromycin
day
ii
number
possibl
complic
cap
may
occur
recognis
patient
fail
respond
first
day
empir
therapi
deterior
initi
improv
complic
parapneumon
effus
empyema
repeat
cxr
perform
patient
fail
respond
first
day
empir
therapi
deterior
initi
improv
ii
followup
cxr
demonstr
effus
lung
abscess
imag
ct
thorac
ultrasonographi
consid
b
ii
signific
amount
pleural
fluid
prompt
diagnost
pleurocentesi
exclud
empyema
ii
fluid
drainag
mean
intercost
drain
necessari
case
complic
parapneumon
effus
empyema
ii
lung
abscess
patient
diagnos
lung
abscess
complic
cap
receiv
prolong
cours
antibiot
usual
week
along
physiotherapi
effect
postur
drainag
b
ii
patient
cap
wellrecognis
risk
factor
cardiovascular
event
case
fail
show
adequ
clinic
recoveri
investig
possibl
cardiovascular
event
iii
term
aspir
refer
abnorm
entri
larg
inoculum
exogen
substanc
endogen
secret
lower
airway
caus
pneumon
pneumonia
import
clinic
microbiolog
differ
cap
acut
aspir
event
particularli
absenc
system
inflamm
impair
respiratori
function
requir
antimicrobi
therapi
even
associ
new
cxr
infiltr
iii
antimicrobi
consid
patient
aspir
pneumon
persist
progress
sign
symptom
hour
aspir
b
iii
aspir
pneumonia
may
indol
process
usual
occur
late
aspir
event
may
associ
suppur
complic
diagnosi
impli
bacteri
infect
lung
therefor
indic
antimicrobi
therapi
ii
recommend
empir
antibiot
therapi
amoxicillinclavulan
cephalosporin
plu
clindamycin
metronidazol
may
accept
altern
b
ii
cap
caus
consider
morbid
mortal
throughout
world
improv
care
patient
cap
south
africa
particularli
import
high
burden
diseas
need
improv
standard
antibiot
prescrib
face
rise
amr
number
import
intern
guidelin
includ
infecti
diseas
societi
america
idsa
american
thorac
societi
at
british
thorac
societi
bt
howev
south
africa
repres
uniqu
environ
high
preval
hiv
infect
amr
guidelin
must
local
applic
group
interest
approach
manag
cap
south
africa
includ
south
african
thorac
societi
sat
feder
infecti
diseas
societi
southern
africa
fidssa
guidelin
auspic
sat
fidssa
repres
updat
sat
cap
guidelin
publish
purpos
document
updat
clinician
regard
import
advanc
controversi
manag
patient
cap
south
africa
high
preval
hiv
infect
risk
factor
number
pulmonari
infect
overlap
present
includ
tuberculosi
pneumocysti
jirovecii
pneumonia
pcp
guidelin
seek
provid
practic
advic
approach
adult
patient
acut
communityacquir
infect
lung
parenchyma
guidelin
appli
much
larger
group
adult
nonpneumon
lower
respiratori
tract
infect
lrti
includ
acut
bronchiti
acut
exacerb
chronic
obstruct
pulmonari
diseas
ill
label
chest
infect
pneumonia
nonambulatori
resid
nurs
home
longterm
care
facil
epidemiolog
mirror
healthcareassoci
pneumonia
hcap
treat
accord
institut
hcap
guidelin
committe
specialist
sat
fidssa
assembl
individu
andor
small
group
assign
write
section
guidelin
nonsystemat
literatur
search
undertaken
identifi
publish
evid
relev
section
search
conduct
pubm
cochran
librari
databas
well
check
refer
list
highli
relev
paper
recent
intern
cap
guidelin
section
collat
distribut
entir
group
comment
disagr
resolv
onlin
discuss
comment
address
committe
agre
final
draft
guidelin
attempt
made
align
guidelin
depart
health
essenti
medicin
list
howev
aim
public
privat
sector
therefor
differ
respect
committe
recognis
patient
cap
care
primari
care
intern
medicin
emerg
medicin
physician
guidelin
therefor
direct
primarili
strength
recommend
guidelin
illustr
box
influenza
pneumonia
along
tuberculosi
amongst
top
five
lead
underli
natur
caus
death
south
african
adult
age
year
incid
lrti
amongst
individu
age
year
south
africa
approxim
per
popul
peak
incid
individu
age
year
like
driven
high
hiv
preval
age
group
underli
hiv
infect
import
risk
condit
lrti
hospitalis
south
africa
hiv
preval
among
hospitalis
patient
age
year
among
age
year
document
sentinel
surveil
site
south
africa
hivinfect
individu
substanti
greater
risk
hospitalis
lrti
hivuninfect
individu
import
risk
factor
hospitalis
lrti
adult
includ
increas
age
underli
lung
diseas
asthma
chronic
obstruct
airway
diseas
south
africa
case
fatal
ratio
cfr
adult
hospitalis
lrti
hivinfect
individu
experienc
higher
cfr
hivuninfect
individu
signific
predictor
mortal
set
increas
agegroup
receiv
mechan
ventil
supplement
oxygen
mani
organ
caus
pneumonia
adult
mix
infect
multipl
viral
andor
bacteri
infect
common
streptococcu
pneumonia
common
caus
cap
approxim
adult
cap
prepneumococc
conjug
vaccin
pcv
era
although
incid
invas
pneumococc
strong
recommend
use
b
moder
recommend
use
c
weak
recommend
use
qualiti
evid
evid
least
properli
randomis
control
trial
ii
evid
least
welldesign
clinic
trial
without
randomis
cohort
casecontrol
analyt
studi
prefer
centr
multipl
timeseri
dramat
result
uncontrol
experi
iii
evid
opinion
respect
author
base
clinic
experi
descript
studi
report
expert
committe
pneumonia
south
african
adult
decreas
result
indirect
effect
follow
introduct
pcv
routin
infant
immunis
programm
bacteri
caus
pneumonia
includ
haemophilu
influenza
staphylococcu
aureu
gramneg
bacilli
klebsiella
pneumonia
atyp
bacteri
caus
pneumonia
uncommon
south
africa
adult
cap
cyclic
circul
period
increas
incid
eg
legionella
mycoplasma
speci
may
caus
outbreak
bordetella
pertussi
may
present
cap
atyp
older
children
adult
pertussi
identifi
patient
lrti
howev
rate
pertussi
age
may
expect
increas
follow
chang
wholecel
acellular
pertussi
vaccin
routin
infant
immunis
schedul
anaerob
bacteria
may
caus
pneumonia
particularli
patient
increas
risk
aspir
pseudomona
aeruginosa
anoth
uncommon
bacteri
caus
cap
may
consid
individu
sever
pneumonia
especi
underli
malign
cardiovascular
diseas
structur
lung
diseas
eg
cystic
fibrosi
influenza
common
viral
caus
cap
adult
identifi
patient
respiratori
virus
respiratori
syncyti
viru
rhinoviru
adenoviru
may
also
identifi
coinfect
common
respiratori
virus
bacteria
virus
may
also
identifi
healthi
control
respiratori
symptom
therefor
identif
viru
preclud
initi
antibiot
treatment
importantli
patient
cap
south
africa
may
test
posit
tuberculosi
spectrum
aetiolog
agent
hivinfect
individu
may
differ
hivuninfect
individu
streptococcu
pneumonia
tuberculosi
commonli
identifi
hivinfect
individu
addit
import
consid
diagnosi
pcp
preval
among
hivinfect
adult
admit
cap
subsaharan
africa
p
jirovecii
identifi
quantit
pcr
adult
cap
patient
south
africa
howev
case
identif
pcr
may
indic
colonis
risk
cap
hivinfect
individu
well
probabl
identifi
mix
atyp
infect
increas
decreas
cell
count
increas
globalis
increas
contact
animalhuman
interfac
risk
emerg
respiratori
viral
infect
avian
influenza
middl
east
respiratori
syndrom
coronaviru
merscov
infect
remain
present
clinician
keep
updat
regard
global
trend
emerg
virus
cluster
two
individu
hospitalis
sever
respiratori
ill
respiratori
death
identifi
aetiolog
investig
pneumonia
refer
infect
lower
respiratori
tract
result
parenchym
lung
inflamm
symptom
acut
ill
clinic
diagnosi
pneumonia
requir
presenc
compat
symptom
sign
plu
new
worsen
infiltr
cxr
guidelin
patient
suspect
cap
defin
support
clinic
featur
describ
without
cxr
confirm
although
cough
common
reason
present
outpati
care
minor
patient
cap
lrti
includ
acut
bronchiti
commonli
caus
virus
associ
normal
chest
radiograph
requir
antibiot
therapi
recent
randomis
control
trial
involv
outpati
lrti
pneumonia
suspect
group
assign
amoxicillin
benefit
term
durat
sever
symptom
side
effect
significantli
common
receiv
antibiot
compar
placebo
translat
net
harm
effect
similar
find
observ
clinic
trial
emphasis
need
correctli
identifi
cap
limit
overus
antibiot
appropri
treat
refer
seriou
infect
without
benefit
cxr
diagnosi
cap
outpati
set
challeng
reli
clinic
find
avail
pointofcar
poc
biomark
suggest
way
diagnos
cap
primari
care
cxr
unavail
use
clinic
featur
crp
recent
present
accuraci
clinic
criteria
diagnos
cap
poor
systemat
review
shown
even
combin
symptom
sign
rare
increas
probabl
diagnosi
howev
absenc
vital
sign
abnorm
rel
reliabl
way
exclud
diagnosi
one
studi
found
patient
present
lrti
normal
vital
sign
clinic
examin
low
risk
pneumonia
could
use
rule
diagnosi
case
without
use
cxr
although
poor
correl
clinic
find
radiolog
confirm
cap
physician
primari
care
reli
histori
examin
exclud
diagnos
diseas
follow
featur
commonli
associ
cap
sought
patient
present
acut
cough
primari
care
symptom
acut
lrticough
pleurit
chest
pain
short
breath
sputum
product
absenc
rhinorrhoea
sore
throat
new
focal
chest
sign
examinationlocalis
bronchial
breath
crackl
dull
percuss
decreas
chest
expans
system
abnormalitiestemperatur
subject
fever
chill
sweat
tachycardia
explan
illnessacut
aspir
carcinoma
pulmonari
embol
pulmonari
oedema
acut
exacerb
copd
pneumonia
lead
caus
morbid
mortal
elderli
increas
risk
diseas
immunosenesc
concomit
ill
atyp
present
common
lead
delay
diagnosi
treatment
fever
cough
frequent
absent
frail
older
adult
cap
may
manifest
new
worsen
confus
deterior
function
statu
decompens
underli
ill
addit
nonspecif
clinic
find
elderli
commonli
normal
cxr
make
diagnosi
especi
challeng
cap
diagnos
patient
primari
care
present
combin
wellestablish
clinic
featur
cap
includ
vital
sign
examin
abnorm
ii
principl
cap
diagnosi
patient
present
hospit
outpati
contrast
primari
care
xray
wide
avail
patient
present
hospit
suspect
cap
requir
cxr
confirm
diagnosi
exclud
potenti
caus
ill
accuraci
cxr
diagnosi
pneumonia
known
consid
refer
standard
rulingout
diagnosi
cap
normal
howev
even
normal
cxr
suffici
elimin
diagnosi
set
high
pretest
probabl
cxr
good
test
rulingin
cap
altern
diagnos
consid
patient
abnorm
cxr
absenc
compat
clinic
featur
cap
therefor
infecti
diseas
diagnosi
cap
sever
ill
patient
depend
likelihood
risk
diseas
find
support
featur
use
combin
histori
examin
chest
radiographi
sever
ill
hospitalis
patient
suspect
pneumonia
normal
cxr
unreason
start
empir
antibiot
therapi
may
stop
appropri
cultur
neg
repeat
cxr
hour
remain
clear
new
infiltr
support
larg
cohort
studi
patient
admit
suspect
cap
initi
normal
cxr
develop
chang
consist
cap
repeat
cxr
circumst
howev
administr
antibiot
suspect
cap
without
cxr
confirm
associ
inaccur
diagnosi
overus
antibiot
cxr
perform
patient
present
hospit
suspect
cap
ii
vast
major
case
normal
cxr
exclud
diagnosi
cap
howev
empir
antibiot
therapi
consid
sever
ill
hospitalis
patient
suspect
cap
neg
cxr
studi
cap
exclud
repeat
cxr
hour
neg
iii
number
assess
tool
develop
assist
clinician
assess
sever
cap
advantag
limit
howev
assess
sever
infect
import
sinc
determin
appropri
site
care
extent
microbiolog
workup
choic
initi
empir
antibiot
treatment
one
score
system
recommend
use
patient
admit
hospit
score
deriv
bt
rule
origin
intern
deriv
valid
studi
publish
although
also
valid
set
formal
valid
south
african
set
case
score
system
score
system
use
compon
name
confus
urea
mmoll
respiratori
rate
breathsmin
low
blood
pressur
systol
mmhg
andor
diastol
mmhg
age
year
point
assign
paramet
present
patient
score
system
recommend
use
simplic
also
accuraci
similar
complic
score
system
pneumonia
sever
index
psi
variat
requir
measur
serum
urea
thu
make
particularli
suitabl
outpati
use
although
may
littl
less
accur
potenti
accuraci
score
determin
need
hospitalis
patient
cap
emerg
depart
teach
hospit
johannesburg
set
resourc
constraint
high
hiv
infect
preval
evalu
prospect
observ
studi
singl
centr
although
intervent
studi
document
accur
predict
time
clinic
stabil
risk
death
patient
cap
appear
investig
implement
set
would
perform
well
decisionmak
regard
need
hospit
admiss
patient
none
score
system
replac
clinic
assess
import
addit
factor
socioeconom
depriv
comorbid
must
also
influenc
decis
hospitalis
treatment
score
outpati
recommend
diseas
sever
score
patient
cap
ii
sever
score
system
sole
basi
make
decis
regard
site
care
diseas
sever
score
alway
interpret
conjunct
thorough
clinic
assess
patient
ii
patient
may
refer
primari
care
hospit
confirm
diagnosi
addit
test
cxr
admiss
warrant
patient
seen
emerg
depart
confirm
cap
decis
must
made
regard
need
admiss
decis
base
combin
object
sever
score
clinic
assess
factor
advanc
age
presenc
signific
comorbid
condit
hiv
infect
copd
social
circumst
gener
patient
seen
primari
care
score
consid
treatment
home
score
consid
referr
admiss
hospit
decis
admit
patient
seen
emerg
depart
confirm
cap
base
score
supplement
subject
clinic
assess
prefer
manag
patient
cap
outsid
hospit
increas
cost
complic
rate
associ
hospit
admiss
patient
score
thought
mild
infect
potenti
suitabl
manag
home
patient
score
consid
moder
ill
need
observ
hospit
least
initi
patient
score
thought
sever
ill
therefor
case
especi
score
need
evalu
possibl
admiss
highcar
even
intens
care
unit
patient
score
score
low
risk
death
may
consid
treatment
home
b
ii
patient
score
score
increas
risk
death
refer
hospit
ii
patient
score
high
risk
death
requir
urgent
hospit
admiss
even
consider
admiss
highcar
intens
care
unit
ii
crp
use
diagnosi
cap
doubt
although
primari
care
set
less
like
test
avail
one
except
pointofcar
crp
machin
avail
primari
healthcar
facil
particularli
privat
sector
systemat
review
metaanalysi
crp
use
patient
respiratori
tract
infect
present
primari
care
facil
show
signific
reduct
antibiot
use
suggest
may
lead
slightli
hospit
admiss
cap
confirm
clinic
present
cxr
valu
crp
limit
rais
almost
case
conflict
data
regard
use
prognost
marker
poor
discrimin
differ
aetiolog
cap
tb
cap
crp
sensit
marker
respons
therapi
failur
fall
day
associ
increas
mortal
practic
howev
clinic
evalu
includ
serial
measur
temperatur
like
suffici
identifi
patient
requir
investig
andor
chang
antibiot
therapi
use
procalcitonin
guid
initi
discontinu
antibiot
patient
rang
respiratori
tract
infect
across
rang
set
shown
signific
reduct
use
antibiot
increas
mortal
treatment
failur
howev
subgroup
analysi
patient
cap
show
littl
differ
proport
patient
initi
prescrib
antibiot
therefor
recommend
procalcitonin
measur
diagnosi
cap
confirm
procalcitonin
expens
routin
measur
guid
durat
antibiot
recommend
full
blood
count
fbc
limit
diagnost
valu
cap
rais
white
cell
count
wcc
implic
bacteri
aetiolog
exclud
count
normal
fbc
valu
diagnosi
doubt
altern
diagnos
sought
routin
measur
urea
patient
cap
import
form
part
sever
score
routin
measur
liver
function
recommend
routin
measur
crp
pct
diagnosi
doubt
discourag
may
use
measur
respons
therapi
critic
ill
iii
measur
crp
particularli
primari
care
set
cxr
unavail
may
aid
diagnosi
cap
ii
measur
crp
pct
emerg
depart
may
consid
patient
acut
respiratori
ill
diagnosi
cap
doubt
b
ii
urea
measur
hospitalis
patient
cap
assist
sever
score
microbiolog
investig
perform
order
identifi
aetiolog
agent
intend
confirm
diagnosi
cap
diagnos
primarili
clinic
radiolog
common
microbiolog
investig
would
perform
set
cap
bc
sputum
cultur
detect
legionella
pneumococc
antigen
urin
addit
molecular
test
becom
commonli
employ
serolog
may
also
use
benefit
identifi
aetiolog
agent
primarili
assist
direct
antimicrobi
therapi
result
either
chang
broaden
spectrum
activ
organ
adequ
treat
initi
empir
regimen
would
directli
benefit
patient
chang
narrow
spectrum
agent
suscept
organ
identifi
less
like
directli
benefit
patient
line
antibiot
stewardship
principl
hope
broader
benefit
societi
reason
attempt
identifi
aetiolog
agent
identifi
organ
potenti
public
health
import
eg
influenza
better
understand
epidemiolog
capwhich
turn
influenc
clinic
practic
howev
investig
associ
increas
health
care
cost
decis
whether
perform
microbiolog
investig
patient
cap
sometim
debat
gener
rule
investig
would
recommend
reason
chanc
result
influenc
manag
patient
yield
bc
set
cap
rang
guidelin
appropri
collect
bc
publish
review
likelihood
patient
cap
posit
bc
increas
sever
ill
number
studi
describ
clinic
paramet
associ
increas
chanc
posit
bc
due
differ
studi
design
clinic
paramet
describ
differ
studi
identifi
differ
paramet
associ
bacteraemia
includ
neutrophilia
low
wcc
rais
creatinin
hypoglycaemia
temperatur
elev
psi
score
tachycardia
tachypnoea
hypotens
low
oxygen
satur
use
sputum
identifi
aetiolog
agent
bedevil
need
adequ
sputum
sampl
adequ
sampl
collect
assess
presenc
neutrophil
absenc
epitheli
cell
gram
stain
may
posit
patient
bacterem
pneumococc
pneumonia
patient
bacterem
staphylococcu
aureu
pneumonia
patient
gramneg
bacteraemia
thu
major
benefit
gram
stain
wellcollect
sputum
sampl
may
allow
broaden
antimicrobi
cover
aureu
gramneg
bacilli
howev
must
born
mind
major
patient
microscopi
unhelp
predomin
microorgan
observ
approxim
patient
adequ
sampl
obtain
yield
cultur
adequ
sampl
high
howev
assess
sputum
cultur
yield
patient
cap
low
overal
sinc
proport
patient
unabl
produc
sputum
proport
sampl
unsatisfactori
bc
sputum
sampl
sent
cultur
result
like
influenc
patient
manag
two
commerci
avail
urin
antigen
test
uat
legionella
pneumophila
serogroup
streptococcu
pneumonia
legionella
antigen
test
high
specif
sensit
well
defin
pneumococc
antigen
test
sensit
specif
major
issu
test
whether
posit
result
significantli
alter
therapi
addit
pneumococc
antigen
test
question
increment
yield
obtain
sputum
bc
recent
metaanalysi
found
uat
may
identifi
addit
patient
pneumococc
pneumonia
identifi
cultur
howev
studi
switzerland
found
addit
uat
pneumonia
influenc
antibiot
choic
clinic
outcom
given
empir
regimen
cap
alway
includ
agent
activ
pneumonia
surpris
similar
argument
could
made
regard
use
legionella
uat
sinc
patient
sever
cap
treat
agent
activ
pathogen
howev
readili
avail
altern
test
detect
legionella
knowledg
may
epidemiolog
import
thu
research
need
guid
practic
regard
narrow
spectrum
uat
posit
may
justif
test
patient
sever
cap
legionella
use
uat
rapid
antigen
detect
test
radt
also
avail
influenza
earlier
version
assay
rel
poor
sensit
although
recent
version
improv
sensit
concern
still
sensit
molecular
assay
also
littl
evid
date
clinic
impact
use
radt
prefer
molecular
assay
influenza
addit
molecular
test
diagnost
armamentarium
significantli
increas
proport
patient
aetiolog
agent
foundup
major
addit
agent
viral
although
molecular
test
offer
abil
detect
socal
atyp
pathogen
challeng
howev
remain
determin
whether
presenc
posit
molecular
result
prove
causal
sinc
virus
may
found
proport
asymptomat
patient
addit
mani
viral
pathogen
specif
treatment
apart
influenza
except
discuss
influenza
specif
treatment
avail
detect
influenza
epidemiolog
public
health
implic
molecular
assay
also
offer
rapid
reliabl
method
detect
influenza
present
although
rapid
antigen
test
may
prove
superior
cost
effect
futur
major
disadvantag
serolog
investig
pathogen
legionella
chlamydophila
mycoplasma
spp
need
acut
convalesc
sera
allow
appropri
interpret
result
thu
result
impact
immedi
patient
manag
routin
use
serolog
recommend
patient
admit
icu
subacut
ill
respond
empir
antimicrobi
therapi
tradit
diagnost
test
tb
major
drawback
autom
liquid
cultur
system
gold
standard
diagnosi
tb
expens
requir
prolong
incub
sputum
smear
microscopi
much
lower
diagnost
yield
particularli
hivinfect
patient
provid
drug
suscept
data
respons
limit
ndoh
recent
roll
genexpert
xpert
cepheid
sunnyval
ca
usa
replac
smear
microscopi
diagnos
pulmonari
tb
south
africa
assay
overal
pool
sensit
detect
cultureposit
tb
case
neg
smear
microscopi
result
major
advantag
test
abl
rapidli
detect
patient
rifampicin
resist
sputum
induct
provid
adequ
sampl
bacteriolog
diagnosi
frequent
instruct
healthcar
worker
costlier
result
higher
proport
sameday
diagnos
endors
clinic
valid
rapid
molecular
tb
test
also
use
south
africa
certain
genotyp
assay
line
probe
assay
may
diagnost
accuraci
compar
xpert
mtbrif
ad
advantag
detect
isoniazid
rifampicin
resist
well
suscept
second
line
tb
drug
grow
evid
base
urinebas
tb
lipoarabinomannan
lam
test
hivinfect
patient
rapid
point
care
later
flow
assay
avail
test
perform
particularli
well
hivinfect
patient
count
studi
shown
sensit
inpati
confirm
tb
abil
detect
sickest
patient
advanc
immunosuppress
appropri
train
lam
test
perform
system
qualiti
control
implement
facil
test
use
follow
high
risk
patient
group
present
cap
low
threshold
investig
pulmonari
tb
hivinfect
diabet
admiss
icu
subacut
ill
respond
empir
antimicrobi
therapi
ii
genexpert
mtbrif
tm
cepheid
sunnyval
usa
assay
perform
singl
expector
induc
sputum
specimen
prefer
first
line
diagnost
test
pulmonari
tb
altern
endors
rapid
molecular
test
line
probe
assay
recommend
readili
avail
ii
tb
cultur
perform
follow
patient
neg
genexpert
mtbrif
nonresolv
pneumonia
ongo
suspicion
tb
iii
sputum
unavail
determin
tm
tblam
ag
aler
waltham
usa
test
perform
hivinfect
patient
count
stage
diseas
present
cap
investig
pneumocysti
pneumonia
pcp
typic
present
subacut
ill
constitut
symptom
dri
cough
characteris
bilater
infiltr
cxr
normal
chest
auscult
desatur
puls
oximetri
minim
exert
may
progress
respiratori
failur
ard
carri
overal
case
fatal
gold
standard
diagnost
test
pcp
immunofluoresc
stain
ifa
p
jirovecii
organ
bronchoalveolar
lavag
sampl
test
requir
invas
procedur
wide
avail
south
africa
therefor
rare
use
diagnos
pcp
immunohistochem
stain
ifa
silver
stain
commonli
request
expector
induc
sputum
sampl
sensit
test
poor
inadequ
rule
diagnosi
pcp
sensit
pcr
assay
includ
commerci
assay
develop
evalu
varieti
respiratori
specimen
unfortun
hivassoci
pcp
well
repres
evalu
studi
assay
avail
routin
use
public
sector
south
africa
whilst
good
sensit
low
specif
routin
recommend
plasma
betaglucan
lactat
dehydrogenas
ldh
use
support
investig
limit
evid
efficaci
south
african
set
therefor
use
betaglucan
recommend
part
clinic
registri
trial
limit
clinic
assess
remain
common
method
diagnosi
pcp
sa
base
case
definit
box
clinic
case
definit
use
clinic
diagnos
pcp
b
iii
diagnost
test
hivinfect
patient
fit
case
definit
pcp
suspect
clinic
ground
depend
local
avail
test
may
includ
ifa
dfat
pcr
b
iii
prefer
specimen
diagnost
test
pcp
bal
although
induc
expector
sputum
may
use
bronchoscopi
unavail
b
ii
limit
evid
support
use
betaglucan
diagnos
pcp
south
african
set
use
recommend
part
clinic
registri
trial
iii
choic
initi
antibiot
cap
south
africa
depend
set
patient
treat
age
use
antibiot
within
past
day
presenc
comorbid
cardiovascular
diseas
chronic
respiratori
diseas
chronic
renal
failur
diabet
mellitu
hiv
infect
drug
intoler
recent
systemat
review
found
enough
trial
compar
effect
differ
antibiot
pneumonia
acquir
treat
commun
guidanc
therefor
base
expert
opinion
tabl
figur
algorithm
manag
communityacquir
pneumonia
adult
south
africa
reason
presenc
comorbid
consid
import
reason
modifi
broaden
antibiot
treatment
current
guidelin
relat
number
studi
undertaken
document
associ
distinct
aetiolog
pattern
patient
cap
frequent
associ
broader
spectrum
pathogen
studi
ruiz
colleagu
comorbid
pulmonari
diseas
hepat
nervou
system
ill
well
current
smoke
alcohol
abus
associ
distinct
pattern
aetiolog
condit
studi
respiratori
comorbid
defin
treatment
asthma
copd
presenc
interstiti
lung
disord
hepat
comorbid
defin
preexist
viral
toxic
hepatopathi
nervou
system
ill
defin
symptomat
acut
chronic
vascular
nonvascular
encephalopathi
without
dementia
exampl
studi
patient
pulmonari
disord
greater
risk
infect
gramneg
enter
bacilli
pseudomona
aeruginosa
studi
elsolh
et
al
activ
daili
live
index
pulmonari
defin
treatment
copd
interstiti
lung
diseas
endocrin
defin
diabet
mellitu
cn
defin
symptomat
acut
chronic
vascular
nonvascular
encephalopathi
comorbid
associ
similar
box
case
definit
pcp
patient
hiv
dyspnoea
exert
nonproduct
cough
recent
onset
within
past
three
month
tachypnoea
fever
chest
xray
evid
diffus
bilater
interstiti
infiltr
evid
bacteri
pneumonia
bilater
crackl
auscult
without
reduc
breath
sound
distinct
aetiolog
pattern
studi
cilloniz
cowork
document
pathogen
aureu
enterobacteriacea
pseudomona
aeruginosa
h
influenza
occur
cap
patient
one
comorbid
includ
one
follow
chronic
respiratori
diseas
diabet
mellitu
chronic
cardiovascular
diseas
neurolog
diseas
chronic
liver
diseas
chronic
renal
diseas
comorbid
defin
addit
multipl
medic
comorbid
condit
document
risk
factor
penicillinresist
drugresist
pneumococc
infect
patient
treat
home
year
old
without
antibiot
exposur
past
day
comorbid
receiv
oral
high
dose
amoxicillin
patient
treat
home
year
old
receiv
antibiot
within
previou
day
comorbid
receiv
oral
amoxicillinclavulan
oral
second
gener
cephalosporin
group
altern
oral
respiratori
fluoroquinolon
sever
betalactam
allergi
patient
admit
hospit
treat
intraven
ampicillin
penicillin
first
instanc
unless
year
recent
antibiot
exposur
comorbid
amoxicillinclavulan
cefuroxim
third
gener
cephalosporin
ceftriaxon
cefotaxim
use
altern
respiratori
fluoroquinolon
equal
effect
give
oral
intraven
emerg
evid
patient
sever
pneumonia
either
pneumococc
nonpneumococc
aetiolog
includ
critic
ill
case
combin
antibiot
therapi
commonli
addit
macrolid
agent
standard
betalactam
therapi
may
associ
better
outcom
monotherapi
recent
systemat
review
metaanalys
critic
ill
patient
cap
compar
macrolidebas
therapi
regimen
clearli
indic
macrolid
use
associ
signific
reduct
mortal
compar
nonmacrolid
contain
regimen
benefit
becam
even
signific
pool
data
studi
provid
adjust
risk
estim
mortal
benefit
use
macrolidebas
combin
antibiot
regimen
versu
antibiot
regimen
critic
ill
patient
also
support
studi
surviv
among
intub
patient
cap
among
cap
patient
sever
sepsi
latter
even
evalu
patient
cap
infect
due
macrolideresist
pathogen
eg
macrolideresist
pneumococci
gramneg
pathogen
patient
sever
cap
therefor
treat
combin
amoxicillinclavulan
cefuroxim
third
gener
ceftriaxon
cefotaxim
cephalosporin
plu
macrolideazalid
antibiot
altern
regimen
sever
cap
respiratori
fluoroquinolon
combin
anoth
agent
commonli
betalactam
adult
hospitalis
cap
antibiot
therapi
initi
within
hour
hospit
arriv
associ
lower
adjust
shortterm
mortal
area
epidemiolog
high
rate
penicillinresist
pneumonia
prsp
pharmacokinet
enhanc
amoxicillinclavulan
mg
mg
clavulan
may
prefer
agent
signific
macrolid
resist
preclud
routin
use
agent
monotherapi
mani
patient
cap
area
low
macrolid
resist
young
otherwis
healthi
adult
recent
receiv
cours
antibiot
agent
may
use
particularli
set
sever
betalactam
allergi
macrolideazalidetetracyclin
may
also
use
alon
combin
anoth
agent
case
suspect
known
infect
socal
atyp
pathogen
patient
treat
home
year
old
without
antibiot
exposur
past
day
comorbid
receiv
oral
high
dose
amoxicillin
ii
patient
treat
home
year
old
without
antibiot
exposur
past
day
comorbid
amoxicillinclavulan
cefuroxim
third
gener
cephalosporin
ceftriaxon
cefotaxim
plu
macrolid
antibiot
ii
respiratori
fluoroquinolon
moxifloxacin
levofloxacin
altern
therapi
activ
tuberculosi
agent
use
first
line
cap
may
use
patient
sever
betalactam
allergi
altern
betalactammacrolid
therapi
reserv
use
patient
altern
treatment
option
ii
antibiot
administ
earli
prefer
within
emerg
unit
patient
confirm
cap
ii
although
microbiolog
confirm
aetiolog
cap
obtain
minor
case
import
caus
organ
identifi
antibiot
chang
narrowest
spectrum
agent
effect
treat
organ
caus
organ
resist
initi
therapi
necessari
use
broader
spectrum
agent
although
standard
agent
may
use
patient
highlevel
resist
two
agent
use
empir
therapi
may
use
c
e
f
r
l
n
e
f
l
n
e
w
b
r
p
e
c
r
u
cephalosporin
prodrug
exhibit
bactericid
activ
gramposit
pathogen
includ
methicillinresist
staphylococcu
aureu
mrsa
pneumonia
well
gramneg
pathogen
integr
analysi
two
registr
studi
ceftarolin
commun
acquir
pneumonia
trial
versu
ceftriaxon
hospit
patient
focu
focu
compar
ceftarolin
ceftriaxon
treatment
adult
patient
requir
hospitalis
cap
demonstr
clinic
cure
rate
ceftarolin
group
numer
higher
ceftriaxon
group
agent
well
toler
safeti
profil
similar
ceftriaxon
ceftarolin
reserv
use
patient
microbiolog
confirm
cap
due
penicillinresist
pneumonia
penicillin
mic
mgl
mrsa
ertapenem
group
carbapenem
limit
activ
nonfer
gramneg
bacilli
excel
vitro
activ
ie
isol
ertapenem
mic
less
equal
suscept
breakpoint
bacteria
gener
associ
cap
pneumonia
methicillinsuscept
staphylococcu
aureu
mssa
mani
haemophilu
spp
enterobacteriacea
includ
extendedspectrum
esbl
produc
strain
anaerob
efficaci
safeti
ertapenem
treatment
cap
requir
parenter
therapi
compar
ceftriaxon
two
registr
trial
demonstr
ertapenem
g
day
highli
effect
therapi
cap
hospitalis
adult
moderatetosever
diseas
ertapenem
reserv
use
patient
microbiologicallyconfirm
cap
due
resist
enterobacteriacea
esblproduc
pathogen
case
definit
pcp
patient
hiv
shown
box
patient
hiv
infect
fulfil
criteria
posit
specif
test
pcp
initi
therapi
cotrimoxazol
mgkg
tmp
mgkg
smxday
divid
dose
oral
intraven
prednison
mg
twice
daili
day
follow
mg
daili
day
mg
daili
day
empir
therapi
pcp
ad
patient
fulfil
case
definit
withheld
basi
neg
immunohistochem
stain
sputum
specimen
ii
empir
therapi
tb
prior
initi
test
rare
requir
unless
miliari
pattern
cxr
patient
sever
ill
tb
suspect
iii
influenza
season
south
africa
typic
start
earli
june
run
around
septemb
date
inform
avail
nation
institut
communic
diseas
websit
wwwnicdacza
period
influenza
consid
patient
sever
pneumonia
particularli
histori
preced
upper
respiratori
tract
infect
andor
diffus
bilater
infiltr
cxr
influenza
suspect
ground
patient
initi
oseltamivir
mg
twice
daili
nasopharyng
aspir
test
influenza
polymeras
chain
reaction
specif
risk
factor
sever
influenza
pregnanc
immun
compromis
includ
diabet
mellitu
hiv
infect
obes
chronic
lung
cardiac
neurolog
diseas
age
year
influenza
season
oseltamivir
provid
patient
sever
pneumonia
stop
pcr
test
nasopharyng
aspir
neg
ii
influenza
season
oseltamivir
provid
patient
moder
cap
suspect
influenza
specif
risk
factor
sever
diseas
stop
pcr
test
nasopharyng
aspir
neg
b
ii
sinc
mortal
patient
cap
particularli
need
hospitalis
especi
intens
care
unit
remain
high
even
presenc
effect
antibiot
therapi
studi
ongo
find
effect
adjunct
therapi
could
use
togeth
antibiot
improv
outcom
multipl
agent
recommend
test
result
larg
disappoint
prior
statin
use
shown
systemat
review
metaanalys
associ
decreas
risk
andor
mortal
cap
enough
evid
randomis
control
trial
recommend
routin
use
either
prevent
cap
improv
mortal
randomis
doubleblind
placebocontrol
intervent
studi
investig
impact
statin
use
admiss
patient
cap
hospit
associ
reduct
cytokin
level
associ
reduct
time
clinic
stabil
among
patient
sever
recent
studi
metaanalys
measur
differ
endpoint
shown
definit
benefit
adjunct
corticosteroid
sever
hospitalis
patient
cap
data
gener
studi
systemat
review
recent
extens
review
one
comprehens
metaanalys
siemieniuk
colleagu
addit
undertak
extens
extract
literatur
analys
data
possibl
benefit
potenti
harm
use
instrument
assess
risk
bia
individu
studi
well
public
bia
grade
system
evalu
qualitycertainti
evid
final
assess
find
corticosteroid
use
associ
lower
mortal
signific
sever
cap
group
reduct
need
mechan
ventil
occurr
ard
time
clinic
stabil
length
hospit
stay
evid
moder
higher
qualiti
still
unansw
question
regard
corticosteroid
use
includ
patient
cap
like
benefit
corticosteroid
use
dose
long
howev
data
variou
studi
metaanalys
suggest
sever
cap
requir
icu
admiss
highest
inflammatori
indic
crp
level
mgl
shock
requir
vasopressor
support
like
benefit
recommend
regimen
methylprednison
h
equival
day
patient
diabet
receiv
longterm
steroid
includ
rct
limit
data
patient
hiv
infect
enough
evid
recommend
routin
use
statin
cap
addit
macrolid
standard
betalactam
therapi
associ
better
outcom
patient
sever
cap
requir
icu
admiss
may
relat
antimicrobi
activ
macrolid
may
also
due
antiinflammatori
immunomodulatori
effect
ii
use
system
corticosteroid
eg
methylprednison
h
equival
consid
patient
sever
cap
requir
icu
admiss
unless
influenza
tuberculosi
like
histori
gastrointestin
bleed
within
previou
month
mortal
region
hospitalis
cap
among
admit
icu
obviou
reason
referr
need
mechan
ventil
presenc
septic
shock
otherwis
patient
evalu
icu
admiss
clinic
judgment
howev
import
elderli
immunocompromis
patient
may
warrant
icu
admiss
even
lower
score
organ
caus
sever
cap
similar
caus
less
sever
diseas
pneumonia
legionella
spp
aureu
k
pneumonia
virus
influenza
especi
unvaccin
patient
asthmat
obes
immunocompromis
case
pregnanc
howev
organ
import
consid
especi
right
clinic
geograph
context
influenza
sar
merscov
hantaviru
p
jirovecii
enter
gramneg
bacilli
elderli
aspir
mssa
mrsa
influenza
travel
corticosteroid
diabet
tuberculosi
potenti
use
intervent
includ
relev
patient
sever
sepsi
mechan
ventil
utilis
restor
adequ
oxygen
without
caus
lung
injuri
antibiot
administ
soon
diagnosi
made
prefer
emerg
room
similar
describ
except
intraven
macrolid
administ
sever
pneumonia
particularli
presenc
septic
shock
immunomodulatori
effect
coincident
would
cover
l
pneumophila
whether
initi
suspect
appear
howev
empir
antibiot
coverag
atyp
pathogen
pneumonia
c
pneumonia
improv
surviv
clinic
efficaci
hospitalis
patient
influenza
season
oseltamivir
initi
patient
sever
pneumonia
influenza
suspect
stop
exclud
pcr
patient
influenza
pneumonia
earlier
neuraminidas
inhibitor
start
better
outcom
sever
pneumonia
form
primari
ard
howev
spread
infiltr
may
repres
secondari
ard
due
capillari
leak
antibiot
failur
diagnost
uncertainti
exist
particularli
immunocompromis
patient
bilater
infiltr
pneumocysti
pcr
unavail
use
biomark
includ
crp
pct
probnp
bdg
plasma
betaglucan
extrem
help
elucid
caus
decreas
unnecessari
antibiot
prescript
biomark
may
also
help
identifi
antibiot
failur
declin
crp
gener
indic
antibiot
appropri
despit
worsen
radiolog
featur
earli
ivpo
antibiot
central
pillar
antibiot
stewardship
reduc
cost
intraven
cannula
infect
encourag
reduc
length
hospit
stay
sever
studi
shown
safe
switch
patient
cap
intraven
oral
therapi
becom
clinic
stabl
definit
clinic
stabil
vari
typic
definit
given
box
precis
durat
antibiot
therapi
manag
microbiolog
document
nondocu
cap
inform
robust
evid
durat
therapi
determin
base
clinic
respons
patient
caus
agent
fever
defervesc
rapidli
clinic
improv
safe
stop
betalactam
antibiot
day
patient
show
slow
clinic
improv
confirm
aetiolog
agent
pseudomona
aeruginosa
aureu
gramneg
enter
organ
may
necessari
continu
antibiot
longer
patient
switch
intraven
oral
antibiot
haemodynam
stabl
respiratori
rate
temperatur
abl
take
oral
medic
commun
manag
patient
admit
hospit
low
moder
sever
uncompl
pneumonia
day
appropri
antibiot
recommend
ii
treatment
durat
may
extend
beyond
day
specif
clinic
scenario
staphylococcu
aureu
bacteraemia
ii
patient
confirm
legionella
pneumonia
treat
azithromycin
day
ii
case
pneumonia
resolv
complet
appropri
antibiot
treatment
support
care
howev
number
import
complic
cap
may
occur
requir
specif
manag
complic
consid
whenev
patient
fail
respond
adequ
therapi
although
patient
present
later
gener
ill
health
ongo
constitut
symptom
diagnosi
complic
cap
frequent
delay
clinician
low
threshold
investig
parapneumon
effus
occur
least
bacteri
cap
usual
small
ratio
pleural
fluid
serum
protein
ratio
pleural
fluid
serum
ldh
pleural
fluid
ldh
two
third
upper
limit
normal
serum
valu
recent
systemat
review
pleural
fluid
cholesterol
greater
mgdl
pleural
ldh
greater
ul
better
posit
neg
likelihood
ratio
distinguish
exud
transud
light
criteria
low
pleural
fluid
ph
level
predict
complic
effus
requir
drainag
low
pleural
fluid
glucos
level
case
pleural
fluid
ph
indic
need
urgent
drainag
effus
ph
reason
observ
patient
pleural
fluid
ph
suggest
effus
may
manag
system
antibiot
alon
fluid
drainag
mean
intercost
drain
necessari
case
complic
parapneumon
effus
empyema
current
intern
guidelin
strongli
recommend
routin
use
ultrasonographi
pleural
fluid
drainag
procedur
repeat
cxr
perform
patient
fail
respond
first
day
empir
therapi
deterior
initi
improv
ii
followup
cxr
demonstr
effus
lung
abscess
imag
ct
thorac
ultrasonographi
consid
b
ii
signific
amount
pleural
fluid
prompt
diagnost
pleurocentesi
exclud
empyema
ii
fluid
drainag
mean
intercost
drain
necessari
case
complic
parapneumon
effus
empyema
ii
lung
abscess
defin
necrosi
pulmonari
parenchyma
cavit
acut
lung
abscess
associ
short
durat
symptom
rapidlyevolv
chest
radiograph
rare
complic
cap
risk
factor
includ
immunosuppress
inappropri
antibiot
select
infect
aureu
k
pneumonia
acut
lung
abscess
differenti
chronic
abscess
present
indol
symptom
evolv
period
week
month
seen
commonli
debilit
alcohol
patient
follow
aspir
patient
reduc
level
conscious
impair
swallow
mechan
infect
anaerob
bacteria
aureu
gramneg
enter
bacilli
anginosu
group
previous
known
milleri
presenc
poor
dental
hygien
consid
instanc
lung
abscess
typic
diagnos
chest
radiograph
reveal
pulmonari
infiltr
caviti
airfluid
level
frequent
present
better
anatom
definit
achiev
ct
scan
distinguish
cavit
lung
lesion
pleural
collect
also
complic
cap
may
also
demonstr
previous
unrecognis
underli
condit
aspir
foreign
bodi
pulmonari
neoplasm
bronchial
stenosi
patient
respond
appropri
antibiot
guid
microbiolog
precipit
episod
cap
patient
fail
respond
antibiot
may
necessari
insert
pigtail
drain
antimicrobi
therapi
amoxicillinclavulan
appropri
chronic
abscess
suspect
instanc
sputum
cultur
unreli
contamin
oral
flora
prolong
cours
antibiot
week
may
requir
although
evid
optimum
durat
antimicrobi
therapi
monitor
respons
serial
crp
measur
may
use
guid
length
therapi
percutan
drainag
abscess
guid
either
ultrasound
ct
perform
diagnost
therapeut
nonrespond
surgeri
rare
requir
less
case
seri
patient
diagnos
lung
abscess
complic
cap
receiv
prolong
cours
antibiot
usual
week
along
physiotherapi
effect
postur
drainag
b
ii
emerg
awar
possibl
occurr
cardiovascular
event
patient
cap
one
earliest
studi
cardiac
chang
cap
undertaken
south
africa
regard
cardiac
event
may
includ
acut
myocardi
infarct
ami
new
worsen
cardiac
failur
acut
worsen
arrhythmia
occur
either
alon
combin
document
allcaus
cap
well
pneumococc
cap
specif
cardiovascular
event
common
elderli
patient
underli
cardiac
risk
factor
also
evid
event
may
also
occur
younger
patient
without
histori
clinic
cardiac
diseas
obviou
addit
risk
factor
regard
pathogenesi
increasingli
recognis
platelet
activ
may
play
central
role
capassoci
ami
rais
possibl
antiplatelet
agent
aspirin
among
mani
agent
may
benefici
prevent
event
document
least
one
studi
elderli
furthermor
pathogenesi
cardiac
event
pneumococc
cap
increasingli
understood
recommend
patient
cap
wellrecognis
risk
factor
cardiovascular
event
patient
complic
clinic
failur
investig
possibl
cardiovascular
event
importantli
event
occur
patient
cap
associ
poorer
prognosi
acut
well
poorer
prognosi
associ
increas
risk
cardiovascular
event
longterm
followup
topic
review
detail
elsewher
patient
cap
wellrecognis
risk
factor
cardiovascular
event
case
fail
show
adequ
clinic
recoveri
investig
possibl
cardiovascular
event
iii
cap
occasion
lead
bronchiectasi
particularli
recurr
associ
underli
anatom
immun
defect
bronchiectasi
defin
abnorm
dilat
distort
bronchial
tree
characteris
chronic
sputum
product
persist
airflow
limit
signific
infect
particularli
childhood
caus
structur
damag
impair
mucociliari
clearanc
facilit
chronic
bacteri
infect
time
persist
infect
may
result
bronchiectasi
aetiolog
agent
implic
origin
precipit
bronchial
wall
injuri
includ
mycoplasma
pneumonia
bordetella
pertussi
adenoviru
measl
tuberculosi
remain
import
caus
bronchiectasi
patient
highburden
commun
hiv
infect
term
aspir
refer
abnorm
entri
larg
inoculum
exogen
substanc
endogen
secret
lower
airway
may
result
lung
inflamm
associ
clinic
consequ
resolv
spontan
without
therapi
clinic
present
depend
type
volum
aspir
materi
frequenc
aspir
host
immun
respons
major
syndrom
relat
aspir
includ
airway
obstruct
inhal
particul
matter
aspir
pneumon
chemic
injuri
caus
aspir
steril
liquid
gastric
content
noxiou
fluid
aspir
pneumonia
infecti
process
caus
inhal
oropharyng
secret
colonis
microorgan
case
cap
caus
microaspir
rel
virul
bacteria
resid
upper
respiratori
tract
aspir
pneumonia
refer
syndrom
bacteri
pneumonia
suscept
patient
defect
lower
airway
clearanc
mechan
aspir
larg
inoculum
normal
nonvirul
pathogen
although
featur
aspir
pneumon
aspir
pneumonia
overlap
repres
distinct
clinic
entiti
term
pathophysiolog
mechan
clinic
manifest
treatment
socal
bland
aspir
occur
haematemesi
aspir
enter
feed
may
lead
cxr
infiltr
result
inflammatori
respons
lung
usual
resolv
spontan
without
antimicrobi
therapi
often
failur
clinician
distinguish
aspir
pneumon
bland
aspir
aspir
pneumonia
tendenc
consid
aspir
syndrom
infecti
result
overus
antimicrobi
accur
estim
preval
communityacquir
aspir
pneumonia
caap
limit
lack
standardis
case
definit
studi
distinguish
aspir
pneumon
pneumonia
observ
studi
develop
countri
found
cap
episod
may
result
aspir
stroke
patient
aspir
higher
risk
develop
pneumonia
complic
acut
stroke
associ
significantli
increas
risk
death
patient
caap
like
admit
intens
care
unit
requir
mechan
ventil
nonaspir
cap
significantli
increas
inhospit
mortal
length
stay
primari
predispos
mechan
aspir
includ
dysphagia
alter
mental
statu
result
compromis
glottic
closur
cough
reflex
dysphagia
regard
import
risk
factor
aspir
pneumonia
commonli
due
neurolog
oesophag
disord
also
complic
copd
use
antipsychot
medic
alcohol
abus
seizur
strongli
associ
anaerob
aspir
pneumonia
reduc
level
conscious
poor
oral
hygien
immun
dysfunct
delay
present
condit
dental
cari
periodont
diseas
gingiv
increas
risk
oropharyng
colonis
pathogen
organ
higher
overal
bacteri
load
associ
higher
risk
aspir
pneumonia
elderli
therefor
repres
higher
risk
group
frequent
neglect
oral
hygien
higher
rate
neurolog
diseas
nasogastricor
gastrostomytub
feed
independ
risk
factor
aspir
domin
role
anaerob
organ
aspir
pneumonia
suggest
earli
studi
use
anim
model
invas
diagnost
procedur
transthorac
transtrach
needl
aspir
common
isol
includ
bacteroid
melaninogenicu
bacteroid
speci
fusobacterium
nucleatum
peptostreptococcu
spp
mani
produc
betalactamas
relev
earli
studi
assess
bacteriolog
aspir
pneumonia
question
concern
steril
sampl
techniqu
employ
inclus
patient
establish
complic
lung
abscess
empyema
recent
studi
use
protect
specimen
brush
sampl
lower
respiratori
tract
patient
sever
aspir
pneumonia
isol
bacteri
pathogen
minor
case
studi
pneumonia
aureu
h
influenza
enterobacteriacea
predomin
pathogen
anaerob
organ
isol
group
institutionalis
elder
sever
aspir
pneumonia
underw
bronchoscop
sampl
gramneg
enter
bacilli
predomin
organ
isol
follow
anaerob
bacteria
aureu
shift
microbiolog
profil
may
reflect
true
declin
anaerob
infect
due
improv
social
condit
access
health
care
overlap
organ
found
healthcar
associ
pneumonia
suggest
increas
occurr
aspir
set
earli
clinic
featur
aspir
pneumonia
difficult
distinguish
caus
cap
particularli
aspir
event
usual
wit
diagnosi
usual
made
patient
present
pneumon
process
predisposit
aspir
ie
difficulti
swallow
reduc
level
conscious
plu
involv
depend
pulmonari
segment
posterior
segment
upper
lobe
apic
segment
lower
lobe
aspir
occur
recumb
posit
basal
segment
lower
lobe
upright
posit
particularli
right
lower
lobe
clinic
biochem
find
reliabl
distinguish
anaerob
aspir
pneumonia
cap
follow
may
suggest
anaerob
caus
pneumonia
product
foulsmel
sputum
suggest
infect
anaerob
organ
develop
lung
abscess
necrotis
pneumonia
empyema
onset
complic
may
indol
occur
around
week
aspir
event
contrast
aspir
pneumon
hyperacut
ill
usual
occur
wit
aspir
event
rapidonset
dyspnoea
within
hour
aspir
bronchospasm
bilater
patchi
cxr
infiltr
includ
nondepend
area
frothi
sputum
hypoxia
promin
featur
patient
may
progress
develop
acut
respiratori
distress
syndrom
may
accompani
system
inflammatori
respons
fever
leukocytosi
tachycardia
despit
absenc
infect
base
anim
model
ml
gastric
content
need
aspir
induc
chemic
pneumon
averages
adult
wit
larg
aspir
event
support
diagnosi
frequent
find
anaerob
infect
caap
microbiolog
studi
perform
led
chang
recommend
empir
antibiot
therapi
aspir
pneumonia
shift
away
penicillin
use
agent
specif
anaerob
coverag
clindamycin
metronidazol
betalactambetalactamas
inhibitor
combin
small
rct
conduct
earli
compar
penicillin
clindamycin
patient
lung
abscess
confirm
anaerob
pneumonia
show
much
better
cure
rate
use
clindamycin
acut
aspir
event
particularli
absenc
system
inflamm
impair
respiratori
function
requir
antimicrobi
therapi
even
associ
new
cxr
infiltr
iii
antimicrobi
consid
patient
aspir
pneumon
persist
progress
sign
symptom
hour
aspir
b
iii
aspir
pneumonia
may
indol
process
usual
occur
late
aspir
event
may
associ
suppur
complic
diagnosi
impli
bacteri
infect
lung
therefor
indic
antimicrobi
therapi
ii
recommend
empir
antibiot
therapi
amoxicillinclavulan
cephalosporin
plu
clindamycin
metronidazol
may
accept
altern
b
ii
implement
south
african
nation
guidelin
vaccin
influenza
pneumococc
infect
may
assist
prevent
cap
see
www
pulmonologycoza
two
pneumococc
vaccin
regist
use
adult
south
africa
polysaccharid
vaccin
pneumococc
conjug
vaccin
indic
report
south
african
pneumococc
vaccin
guidelin
similar
report
recent
advisori
committe
immun
practic
acip
recommend
brief
recommend
use
adult
age
year
underli
comorbid
condit
smoke
cigarett
function
anatom
asplenia
immunocompromis
condit
hiv
infect
haematolog
malign
transplant
patient
also
recommend
use
person
year
age
older
regist
use
adult
south
africa
part
world
base
initi
immunogen
studi
initi
regist
indic
south
africa
use
singl
dose
adult
year
regist
elsewher
howev
end
receiv
registr
south
africa
use
adult
age
year
older
singl
dose
specif
group
high
risk
pneumococc
infect
mention
registr
includ
case
sickl
cell
diseas
hiv
infect
recommend
receiv
least
one
dose
whether
receiv
one
dose
previous
specif
regimen
recommend
patient
haematopoiet
stem
cell
transplant
elsewher
world
usa
also
regist
use
adult
year
underli
comorbid
immunocompromis
condit
adult
year
highrisk
factor
pneumococc
diseas
eg
csf
leak
cochlear
transplant
function
anatom
asplenia
immunocompromis
condit
well
age
year
age
recommend
use
sequenc
recommend
alway
prefer
given
first
individu
previous
vaccin
vaccin
given
first
follow
minimum
month
later
vaccin
case
adult
year
age
highrisk
underli
comorbid
immunocompromis
condit
month
later
individu
year
howev
case
individu
alreadi
vaccin
vaccin
given
minimum
year
vaccin
two
recent
clinic
studi
attest
clinic
efficaci
pcv
adult
differ
set
first
studi
older
pneumococc
conjug
vaccin
predominantli
hivinfect
adult
adolesc
age
year
age
malawi
recent
recov
episod
invas
pneumococc
diseas
randomis
doubleblind
placebo
control
trial
activ
arm
studi
two
dose
given
patient
week
apart
efficaci
vaccin
primari
endpoint
prevent
episod
vaccin
serotyp
serotyp
pneumococc
infect
ci
second
studi
netherland
among
adult
year
evalu
efficaci
prevent
first
episod
vaccin
type
strain
communityacquir
pneumococc
pneumonia
primari
endpoint
nonbacterem
noninvas
pneumococc
cap
invas
pneumococc
diseas
secondari
endpoint
patient
activ
arm
given
one
dose
vaccin
efficaci
primari
endpoint
ci
secondari
endpoint
ci
ci
respect
efficaci
persist
throughout
durat
studi
almost
year
trival
inactiv
influenza
vaccin
licens
influenza
vaccin
avail
south
africa
chang
natur
influenza
virus
year
strain
includ
vaccin
follow
influenza
season
updat
reason
well
limit
durat
effect
influenza
vaccin
recommend
repeat
year
influenza
vaccin
usual
becom
avail
south
africa
march
given
suffici
earli
provid
protect
winter
season
influenza
vaccin
effect
depend
characterist
vaccin
age
health
whether
good
match
circul
virus
virus
contain
vaccin
influenza
type
subtyp
gener
influenza
vaccin
work
best
among
children
year
healthi
adult
older
peopl
year
children
year
sever
immunocompromis
individu
often
poorer
immun
respons
trival
inactiv
influenza
vaccin
iiv
compar
healthi
adult
howev
even
peopl
influenza
vaccin
still
provid
protect
product
eg
highdos
influenza
vaccin
adjuv
vaccin
shown
effect
certain
group
vaccin
avail
south
africa
elderli
influenza
vaccin
shown
reduc
incid
sever
diseas
includ
bronchopneumonia
hospit
admiss
mortal
trival
iiv
shown
provid
protect
hivinfect
adult
without
sever
immunosuppress
vaccin
healthcar
worker
may
decreas
risk
spread
influenza
patient
vaccin
individu
risk
sever
influenza
may
provid
direct
protect
individu
addit
vaccin
individu
close
contact
peopl
risk
sever
influenza
may
provid
indirect
protect
prevent
transmiss
highrisk
individu
group
receiv
influenza
vaccin
shown
box
adult
year
vaccin
receiv
singl
dose
ii
adult
receiv
receiv
singl
dose
one
year
later
ii
adult
year
vaccin
receiv
singl
dose
follow
year
later
ii
adult
year
receiv
receiv
singl
dose
least
one
year
later
ii
younger
adult
year
vaccin
sever
underli
comorbid
immunocompromis
condit
includ
hiv
infect
receiv
singl
dose
follow
least
month
later
ppv
ii
younger
adult
year
previous
receiv
sever
underli
comorbid
immunocompromis
condit
includ
hiv
infect
receiv
singl
dose
one
year
later
ii
women
pregnant
period
influenza
person
adult
children
high
risk
influenza
complic
underli
medic
condit
receiv
regular
medic
care
condit
chronic
pulmonari
includ
tuberculosi
cardiac
diseas
chronic
renal
diseas
diabet
mellitu
similar
metabol
disord
individu
immunosuppress
individu
morbidli
obes
bodi
mass
index
kgm
resid
oldag
home
chronic
care
rehabilit
institut
person
age
year
children
age
month
efficaci
trival
iiv
low
group
person
age
month
year
longterm
aspirin
therapi
adult
children
famili
contact
individu
high
risk
sever
influenza
person
wish
minimis
risk
influenza
acquisit
especi
industri
set
largescal
absente
could
caus
signific
econom
loss
vaccin
avail
approxim
march
june
offer
influenza
vaccin
adult
age
year
offer
annual
influenza
vaccin
adult
specif
chronic
diseas
chronic
pulmonari
includ
tuberculosi
cardiac
diseas
chronic
renal
diseas
diabet
mellitu
similar
metabol
disord
individu
immunosuppress
includ
hivinfect
individu
individu
morbidli
obes
bodi
mass
index
kgm
offer
annual
influenza
vaccin
ii
healthcar
worker
offer
annual
influenza
vaccin
ii
